MajorVitamin K antagonist anticoagulants×Selective COX-2 inhibitor (coxib)
Updated · Methodology
Mechanism
The Spanish acenocoumarol SmPCs, both the originator and a generic, name celecoxib explicitly among the non-steroidal anti-inflammatory drugs (NSAIDs), including cyclo-oxygenase-2 (COX-2) inhibitors, that potentiate the anticoagulant effect of acenocoumarol or impair haemostasis. These drugs raise the risk of bleeding, including gastrointestinal bleeding (acenocoumarol summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Celecoxib itself, like other NSAIDs, can cause ulcers, perforations and bleeding in the stomach and bowel. With anticoagulants, the risk of bleeding may rise (celecoxib SmPC, AEMPS). According to the US label, celecoxib and anticoagulants such as warfarin have a synergistic effect on bleeding. The risk of serious bleeding is higher with the combination than with either drug alone (celecoxib prescribing information, US Food and Drug Administration, FDA). A rise in the prothrombin time has been reported with celecoxib and warfarin, but the documents give no data for acenocoumarol (AEMPS). In vitro, celecoxib did not inhibit CYP2C9 (FDA), the main enzyme that metabolises acenocoumarol (acenocoumarol SmPC, AEMPS).
Symptoms
The main risk is bleeding, above all from the stomach and bowel. Celecoxib can cause ulcers, perforations and bleeding in the upper and lower digestive tract, sometimes fatal. With celecoxib plus warfarin, serious bleeding with a raised prothrombin time has been reported, some of it fatal, mostly in older people (celecoxib summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older, with a history of gastrointestinal bleeding and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds and bleeding gums (acenocoumarol SmPC, AEMPS).
Management
The Spanish acenocoumarol SmPCs, both the originator and a generic, name celecoxib explicitly among the non-steroidal anti-inflammatory drugs (NSAIDs), including cyclo-oxygenase-2 (COX-2) inhibitors. They generally do not recommend combining these drugs with acenocoumarol unless the combination is strictly indicated (acenocoumarol summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). If the combination cannot be avoided, use close and frequent coagulation checks, for example twice a week, both after celecoxib is started and after it is stopped. While the two drugs are taken together, test coagulation more often than usual (acenocoumarol SmPCs, AEMPS). Monitor the international normalised ratio (INR) especially carefully in the first days of celecoxib and when its dose is changed (celecoxib SmPC, AEMPS). Watch for signs of bleeding (celecoxib prescribing information, US Food and Drug Administration, FDA). Use the lowest effective daily dose of celecoxib for the shortest possible time (celecoxib SmPC, AEMPS). Gastrointestinal complications with celecoxib are more likely in older people, with a history of ulcer or bleeding, with other NSAIDs, acetylsalicylic acid or glucocorticoids, and with alcohol use (celecoxib SmPC, AEMPS). Peptic ulcer and gastrointestinal bleeding are contraindications to acenocoumarol, and active peptic ulcer and gastrointestinal bleeding are contraindications to celecoxib (acenocoumarol and celecoxib SmPCs, AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Celebrex (celecoxib) prescribing information (2024)– FDA, DailyMed setid 2d6675e4-5859-4be2-8037-a20ce9f707aa (Viatris Specialty), revised 11/2024, sections 7
- AEMPS: Ficha técnica: Celecoxib (Celebrex 200 mg) (nº registro 63073), secciones 4.4 y 4.5 (2026)– AEMPS, CIMA, nº registro 63073, revisión 07/2026, secciones 4.4 y 4.5
- AEMPS: Ficha técnica: Celecoxib (Celebrex 200 mg) (nº registro 63073), secciones 4.3, 4.4 y 4.5 (2026)– AEMPS, CIMA, nº registro 63073, revisión 07/2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.5 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.5 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol Aurovitas 4 mg (nº registro 88315), sección 4.5 (2025)– AEMPS, CIMA, nº registro 88315 (Acenocumarol Aurovitas 4 mg comprimidos EFG; texto idéntico en 1 mg, nº 88278), revisión 07/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.9 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.9 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.9
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.4 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.4 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.4
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.3 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.3 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.3